Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.
Invest New Drugs
; 38(5): 1540-1549, 2020 10.
Article
en En
| MEDLINE
| ID: mdl-31950374
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Furanos
/
Cetonas
/
Antineoplásicos
Tipo de estudio:
Clinical_trials
/
Observational_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Idioma:
En
Año:
2020
Tipo del documento:
Article